Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | PDE2A | O00408 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30458203 | 1.00 | CYP3A4 (0.54) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL17278085 | 0.89 | MAPT (0.45) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL6640168 | 0.86 | TNF (0.47) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL16431495 | 0.86 | APAF1 (0.48) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL14538274 | 0.86 | TRPA1 (0.54) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL16431829 | 0.86 | APAF1 (0.48) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL15647963 | 0.79 | TNF (0.59) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL20813447 | 0.79 | CYP3A4 (0.53) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL5358941 | 0.79 | TNF (0.57) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 | |
| SCHEMBL15595899 | 0.79 | SMN1; SMN2 (0.57) | CYP3A4PDE10ASMN1; SMN2ACHEUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104072495-B | The preparation method of natural product alkaloid A aptamine | HEBEI UNIVERSITY OF TECHNOLOGY (CN) | 2015-10-07 | — | — | CN | claimed |
| CN-104072495-A | Method for preparing natural product alkaloid Aaptamine | UNIV HEBEI TECHNOLOGY | 2014-10-01 | — | — | CN | claimed |
| US-20260102327-A1 | COSMETIC COMPOSITION FOR SKIN IMPROVEMENT CONTAINING LOW-MOLECULAR-WEIGHT COLLAGEN, COLLAGEN WATER, OR COLLAGEN EXTRACT | SOOY-K CO., LTD. (KR) | 2026-04-16 | — | — | US | disclosed |
| US-20260007711-A1 | NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEIN | PONO LIFESTYLE, LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12357667-B2 | Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, SARS-CoV-2 spike proteins, and mRNA vaccine spike proteins | PONO LIFESTYLE, LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240307474-A1 | Fermented Uni-sourced Nanoemulsion of Nigella sativa or Cannabis sativa For Use in Medical, Cosmetic, and Recreational Indications with a Method of Its Production and Use | APEX MEDICAL DEVICE DESIGN, LLC (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4366775-A1 | FERMENTED UNI-SOURCED NANOEMULSION OF NIGELLA SATIVA OR CANNABIS SATIVA FOR USE IN MEDICAL, COSMETIC, AND RECREATIONAL INDICATIONS WITH A METHOD OF ITS PRODUCTION AND USE | Apex Medical Device Design, LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4327882-A2 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240016874-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUSES | NOVATEK THERAPEUTICS, LLC (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4232160-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUSES | Novatek Therapeutics, LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230138994-A1 | AN ANIMAL AND LIVESTOCK FEED SUPPLEMENT | EDWARD BASILIANUS BASUKI NUGROHO (ID) | 2023-05-04 | — | — | US | disclosed |
| US-20060156485-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-20 | — | — | US | disclosed |
| US-5889018-A | ADMINISTERING TO THE PATIENT SUFFERING FROM ANXIETY A 1-STYRYLISOQUINOLINE COMPOUND AS AN ANXIOLYTIC AGENT | EGIS GYOGYSZERGYAR RT. (HU) | 1999-03-30 | — | — | US | disclosed |
| EP-0680953-A1 | 1-[Styryl]- and 1-[2'-(heteroaryl)-ethenyl]-isoquinoline derivatives, a process for preparing them as well as medicaments containing them and the use of them | EGIS GYOGYSZERGYAR RT. (HU) | 1995-11-08 | — | — | EP | disclosed |
| US-5272270-A | Process for the preparation of 1-alkylisoquinoline derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1993-12-21 | — | — | US | disclosed |
| EP-0471303-A1 | Process for the preparation of 1-alkylisoquinoline derivatives | Consortium für elektrochemische Industrie GmbH (DE) | 1992-02-19 | — | — | EP | disclosed |
| EP-0158312-B1 | 1-CYCLOHEXYL-3,4-DIHYDROISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENT CONTAINING THEM | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1990-09-12 | — | — | EP | disclosed |
| EP-0158312-A2 | 1-Cyclohexyl-3,4-dihydroisoquinoline derivatives, process for their preparation and medicament containing them | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1985-10-16 | — | — | EP | disclosed |
| US-4232160-A | Isoquinoline propionamides exhibiting analgesic properties | MILES LABORATORIES, INC. (US) | 1980-11-04 | — | — | US | disclosed |
| US-3994891-A | VASODILATORS | ARMOUR PHARMACEUTICAL COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102327-A1 | COSMETIC COMPOSITION FOR SKIN IMPROVEMENT CONTAINING LOW-MOLECULAR-WEIGHT COLLAGEN, COLLAGEN WATER, OR COLLAGEN EXTRACT | COL2A1, COL14A1, COL1A1 | CYP3A4 3657/4885PDE10A 1694/4885SMN1; SMN2 3003/4885 |
| US-20260007711-A1 | NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEIN | VDR, RNMT, CD14 | CYP3A4 3159/4885PDE10A 4783/4885SMN1; SMN2 3705/4885 |
| US-20060156485-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, TUBB6, DNMT1 | CYP3A4 526/4885PDE10A 3889/4885SMN1; SMN2 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.